Treatment of Hidradenitis Suppurativa in a Pregnant Patient
Managing hidradenitis suppurativa (HS) during pregnancy requires a carefully adapted approach. The developing embryo places strict constraints on which agents can be used safely, making treatment selection more complex than in the general population.
Clinical Scenario
Pregnancy
Treatment of HS in pregnant women requires special consideration of medication effects on the developing embryo. The standard therapeutic options available for non-pregnant patients cannot all be applied, and the safety profile of each intervention must be weighed carefully.
Treatment Approach
In this setting, first-line management centres on topical treatments, procedural interventions, and lifestyle modifications. Several systemic agents — including certain commonly used drug classes — are contraindicated due to fetal risk. The full regimen, sequencing, and specific agent selection are outlined in the structured protocol…
References
DOI: 10.1016/j.jaad.2019.02.067
Treatment of HS in pregnant women requires special consideration of medication effects on the developing embryo.
In pregnant patients, topical treatments, procedural treatments, and possibly lifestyle modifications, should be considered first-line treatment, whereas systemic agents should be considered second-line treatment.
Avoid retinoids, hormonal agents, most systemic antibiotics, and most immunosuppressive medications in pregnant patients.
View source ↗